We are pleased to announce that Deversify has successfully completed a share issue of SEK 12 million (USD 1.3 million). Powered by the vision that 'Everyone should understand their own health', Deversify offer consumers technical solutions centred around precision health and wellbeing.

We specialise in breathalysers and since the acquisition of Elitista AB education around metabolism. Our solution, personal health data paired with education, provides users with powerful tools to improve their own health. The new funds will primarily be used to scale up sales of Acetrack and Elitista services in Sweden and in Europe.

"With the help of the additional capital, we can continue with the commenced expansion in Europe and also meet the demand in new markets," says Anders Murman, CEO.